STOCK TITAN

Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) - CYTO STOCK NEWS

Welcome to our dedicated page for Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) news (Ticker: CYTO), a resource for investors and traders seeking the latest updates and insights on Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) stock.

Altamira Therapeutics Ltd., formerly known as Auris Medical, is a pioneering company dedicated to developing therapeutics that address significant unmet medical needs. Founded in 2003 and headquartered in Hamilton, Bermuda, with principal operations in Basel, Switzerland, Altamira Therapeutics trades on the NASDAQ Capital Market under the symbol “CYTO”.

Altamira is actively engaged in three primary areas:

  • RNA Therapeutics: Utilizing innovative platforms such as OligoPhore™ and SemaPhore™, the company focuses on developing RNA-based therapies targeting extrahepatic sites. These platforms, currently in the preclinical stage, leverage proprietary peptides to form nanoparticles capable of delivering therapeutic RNA to tissues affected by conditions like solid tumors and inflammation.
  • Nasal Sprays: The commercially available Bentrio™ nasal spray offers protection against airborne viruses and allergens, while AM-125, which is in Phase 2 clinical trials, targets the treatment of vertigo.
  • Inner Ear Disorders: Altamira is progressing with Phase 3 development of Keyzilen® and Sonsuvi® for the intratympanic treatment of tinnitus and hearing loss, respectively.

Altamira Therapeutics is committed to advancing its pipeline through rigorous research and strategic collaborations. Recently, the company has made significant strides with its RNA therapies, as highlighted in studies such as Huang et al. (2021) and Strand et al. (2019), demonstrating the potential of targeting KRAS mutations in cancer. Moreover, ongoing research in peptide-based nanoparticles and NF-κB subunit targeting shows promising applications in inflammatory diseases and cancer treatment.

In the field of nasal sprays, Altamira's Bentrio™ has shown efficacy in clinical trials, with recent studies like Becker et al. (2024) validating its use in protecting against seasonal allergic rhinitis.

Financially, Altamira Therapeutics has reclassified its Bentrio business as discontinued operations, focusing its resources on advancing its core therapeutic areas. The company's investor communications emphasize its forward-looking strategy and commitment to innovation.

Stay updated with the latest news and developments from Altamira Therapeutics by visiting their official website and connecting through their social media channels.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.65%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.87%
Tags
conferences
Rhea-AI Summary

Altamira Therapeutics (Nasdaq:CYTO) announced the publication of positive results from its TRAVERS Phase 2 trial assessing AM-125 (intranasal betahistine) for surgery-induced acute vestibular syndrome (AVS). The study, published in Otology & Neurotology, involved 124 patients across Europe and demonstrated good tolerability alongside significant improvements in balance and vestibular dysfunction symptoms. Specifically, patients receiving 20 mg of AM-125 maintained balance for an average of 10.9 seconds compared to 7.4 seconds for the placebo group (p = 0.08). Altamira plans to submit an IND application to the FDA for AM-125 and aims to partner or divest this asset as it shifts focus towards RNA delivery technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
59.09%
Tags
-
Rhea-AI Summary

Altamira Therapeutics (Nasdaq: CYTO) leverages its peptide-based SemaPhore™ nanoparticle technology to provide an innovative alternative to lipid nanoparticles (LNPs) in mRNA delivery.

SemaPhore offers enhanced stability, non-immunogenic properties, and efficient endosomal release, enabling its use for extrahepatic targets.

With over 840 mRNA programs in development, the limitations of LNPs highlight the significance of SemaPhore's capabilities, including effective cellular uptake and superior delivery rates.

Altamira is focused on serious unmet medical needs, currently advancing two flagship siRNA programs for KRAS-driven cancer and rheumatoid arthritis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-36.23%
Tags
none
-
Rhea-AI Summary

Altamira Therapeutics (Nasdaq:CYTO) announced positive results from a meta-analysis highlighting the effectiveness of betahistine in treating posterior canal benign paroxysmal positional vertigo (BPPV). The study included 860 patients and showed a statistically significant reduction in dizziness handicap when betahistine was added to the Epley maneuver (p = 0.001). The company plans to file an IND application for AM-125, an intranasal formulation of betahistine, with the FDA in May 2023, alongside the protocol for a Phase 2 clinical trial targeting BPPV. This development aligns with Altamira's strategic pivot towards its RNA delivery technology platforms, with intentions to partner or divest AM-125 as a legacy asset.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.5%
Tags
Rhea-AI Summary

Altamira Therapeutics (Nasdaq:CYTO) announced research results indicating that ZBTB46 mRNA nanoparticles, delivered via the SemaPhore™ platform, effectively restricted tumor growth in mice. This study conducted by Washington University highlighted that ZBTB46 expression created an immunostimulatory tumor microenvironment, especially when combined with anti-PD1 immune checkpoint inhibitors. The treatment led to complete remission in several cases, suggesting ZBTB46 as a promising target for cancer therapy. These results may enhance the potential of Altamira's RNA-based therapeutics in oncology and signify a strategic advance in their development pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
none
-
Rhea-AI Summary

Altamira Therapeutics (Nasdaq:CYTO) announced promising results from an animal study demonstrating the efficacy of its SemaPhore delivery platform for mRNA therapeutics in treating osteoarthritis. The study, conducted by leading research groups, showed effective reduction of osteoarthritis progression in mice treated with DNMT3B mRNA nanoparticles. The findings, to be presented at the OARSI World Congress, highlight significant reductions in cartilage degeneration and pain sensitivity in treated subjects. This advancement represents a notable step towards potential disease-modifying therapies for osteoarthritis, which currently affects over 32.5 million US adults.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
none
-
Rhea-AI Summary

Altamira Therapeutics (NASDAQ:CYTO) announced significant findings from a clinical study on its nasal spray Bentrio. The study demonstrated that Bentrio retained effectiveness in nasal passages for up to 210 minutes, significantly longer than the 60 minutes for saline spray. This prolonged duration indicates enhanced protection against airborne allergens. Key insights include Bentrio's formulation allowing extended nasal residence without hindering mucociliary clearance. The research was published in the journal Drug Development and Industrial Pharmacy. The study was conducted with eight healthy volunteers and emphasizes Bentrio's advantages over traditional saline solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.51%
Tags
Rhea-AI Summary

Altamira Therapeutics Ltd. (NASDAQ:CYTO) has filed a provisional patent application for a polyvalent siRNA targeting various KRAS mutations, crucial for advanced cancer therapies. This innovation stems from their OligoPhore™ delivery platform, aimed at enhancing RNA therapeutics' effectiveness. The global market for KRAS inhibitors is projected to exceed $4 billion by 2029, with significant prevalence in cancers like colorectal and pancreatic. Altamira's approach is believed to reduce resistance compared to traditional methods. The company plans to pursue an Investigational New Drug (IND) application with the FDA by late 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
none

FAQ

What is the current stock price of Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) (CYTO)?

The current stock price of Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) (CYTO) is $0.517 as of November 4, 2024.

What is the market cap of Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) (CYTO)?

The market cap of Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) (CYTO) is approximately 1.9M.

What areas of therapeutics does Altamira Therapeutics focus on?

Altamira Therapeutics focuses on RNA therapeutics, nasal sprays for protection against airborne viruses and allergens, and treatments for inner ear disorders.

What are the main products of Altamira Therapeutics?

Main products include the Bentrio™ nasal spray for virus and allergen protection, AM-125 for vertigo treatment, and RNA-based therapies using the OligoPhore™ and SemaPhore™ platforms.

Where is Altamira Therapeutics headquartered?

Altamira Therapeutics is headquartered in Hamilton, Bermuda, with key operations in Basel, Switzerland.

What is the stock symbol for Altamira Therapeutics?

Altamira Therapeutics trades on the NASDAQ Capital Market under the symbol “CYTO”.

What recent achievements has Altamira Therapeutics made in RNA therapeutics?

Altamira has made significant progress in RNA therapeutics, with studies demonstrating the potential of targeting KRAS mutations in cancer and using peptide-based nanoparticles for drug delivery.

What stage are the inner ear disorder treatments in?

Keyzilen® and Sonsuvi®, targeting tinnitus and hearing loss respectively, are currently in Phase 3 clinical development.

How does the OligoPhore™ platform work?

The OligoPhore™ platform complex therapeutic RNAs with proprietary peptides to form nanoparticles, enabling systemic delivery to tissues affected by leaky vasculature, such as in tumors and inflammatory conditions.

What are the recent clinical trial results for Bentrio™?

Recent studies, including those by Becker et al. (2024), have shown that Bentrio™ is effective in protecting against seasonal allergic rhinitis.

What is the significance of recent financial reclassifications for Altamira?

Altamira has reclassified its Bentrio business as discontinued operations to better focus resources on advancing its core therapeutic areas.

How can investors stay updated with Altamira Therapeutics?

Investors can stay updated by visiting Altamira's official website, following their social media channels, and subscribing to their official communications.

Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda)

Nasdaq:CYTO

CYTO Rankings

CYTO Stock Data

1.93M
3.78M
0.53%
0.13%
0.31%
Biotechnology
Healthcare
Link
United States of America
Hamilton